A separate study has demonstrated the therapeutic potential of Wnt‐c59, a PORCN inhibitor with similar potency to CGX1321, when administered orally over a short intervention period (i.e., 2 weeks) in a mouse model of mammary cancer [20]. Here, PORCN is linked to breast cancer.